MediWound to Report First Quarter 2026 Financial Results
Head-To-Head Review: Surrozen (NASDAQ:SRZN) & MediWound (NASDAQ:MDWD)
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
Head-To-Head Analysis: MediWound (NASDAQ:MDWD) & Dyne Therapeutics (NASDAQ:DYN)
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
MediWound Files Annual Report on Form 20-F
MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
MediWound to Present at Upcoming Investor Conferences
MediWound Ltd. (NASDAQ:MDWD) Given Consensus Recommendation of “Moderate Buy” by Analysts
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
MediWound Ltd. (MDWD) Q3 2025 Earnings Call Transcript
MediWound (MDWD) Reports Q3 Loss, Misses Revenue Estimates
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
MediWound to Report Third Quarter 2025 Financial Results
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
MediWound Is A Buy Opportunity On The Dip
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
MediWound to Report Second Quarter 2025 Financial Results
MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
MediWound Ltd.: Undervalued High-Growth Potential
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
MediWound to Report First Quarter 2025 Financial Results
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
MediWound to launch Phase III trial for venous leg ulcers
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?
MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript
MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
MediWound Is A Healthy Investment